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Purpose 
The aim of the project is to use CADD 
techniques to design a drug candidate 
that better inhibits EGFR and 
demonstrate less adverse side effects 
than marketed EGFR TKIs.
Methods 
Seesar SwissAdme
Methodology 
1) PDB codes 
2) SeeSar Modification and Filtration
3) AdmetSar 
4) Pred-hERG
5) SwissAdme 
Erlotinib/Molecule 1
KD: 101.469534 nM KD: 0.000054 nM
x 1879065.44444
Retrieved from SeeSar
Erlotinib
Side Effect Value Probability
Carcinogenicity (binary) - 0.9286
Carcinogenicity (trinary) Non-required 0.5393
Eye corrosion - 0.9897
Eye irritation - 0.9683
Ames mutagenesis - 0.57
Human either-a-go-go inhibition + 0.6978
micronuclear + 0.79
Hepatotoxicity + 0.725
Acute Oral Toxicity (c) III 0.6971
Estrogen receptor binding + 0.8023
Androgen receptor binding + 0.8696
Thyroid receptor binding + 0.836
Glucocorticoid receptor binding + 0.8971
Aromatase binding + 0.8686
PPAR gamma + 0.7436
Honey bee toxicity - 0.6799
Biodegradation - 0.75
crustacea aquatic toxicity - 0.54
Fish aquatic toxicity - 0.5407
Retrieved from AdmetSar and 
LabMol
hERG Inhibition 
Side Effect Value Probability
Carcinogenicity (binary) - 0.7714
Carcinogenicity (trinary) Non-required 0.6508
Eye corrosion - 0.9844
Eye irritation - 0.9794
Ames mutagenesis - 0.67
Human either-a-go-go inhibition + 0.7917
micronuclear + 0.76
Hepatotoxicity - 0.5
Acute Oral Toxicity (c) III 0.6025
Estrogen receptor binding + 0.6001
Androgen receptor binding + 0.6923
Thyroid receptor binding + 0.5514
Glucocorticoid receptor binding - 0.4772
Aromatase binding + 0.6793
PPAR gamma - 0.5306
Honey bee toxicity - 0.6533
Biodegradation - 0.85
crustacea aquatic toxicity + 0.56
Fish aquatic toxicity + 0.8465
Molecule 1 
Retrieved from AdmetSar and 
LabMol
hERG Inhibition 
Erlotinib 
Retrieved from SwissAdme
Molecule 1 
Retrieved from SwissAdme
Conclusions
• To increase binding affinity
• modify 1,2-Dimethoxyethane with nitrogen 
add additional aromatic rings 
• add aromatic rings to imdogen linkers
• To decrease hERG binding 
• add OH 
• linker modification
• non-quinazoline based molecules 
Current Research
(Yin et. al., 2010)
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